LRRC15

Summary

LRRC15 (leucine rich repeat containing 15, HGNC:20818) is a protein-coding gene on chromosome 3q29, encoding Leucine-rich repeat-containing protein 15 (Q8TF66). (Microbial infection) Modulates the ability of SARS-CoV-2 to infect host cells through interaction with the spike protein.

Enables several functions, including fibronectin binding activity; laminin binding activity; and protein sequestering activity. Involved in several processes, including host-mediated suppression of symbiont invasion; negative regulation of protein localization to plasma membrane; and receptor-mediated virion attachment to host cell. Located in collagen-containing extracellular matrix and plasma membrane. Is active in apical plasma membrane.

Source: NCBI Gene 131578 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 132 total
• Druggable target: yes
• MANE Select transcript: NM_130830

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20818
Approved symbol	LRRC15
Name	leucine rich repeat containing 15
Location	3q29
Locus type	gene with protein product
Status	Approved
Aliases	LIB
Ensembl gene	ENSG00000172061
Ensembl biotype	protein_coding
OMIM	619327
Entrez	131578

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000347624, ENST00000428839

RefSeq mRNA: 2 — MANE Select: NM_130830 NM_001135057, NM_130830

CCDS: CCDS3306, CCDS46984

Canonical transcript exons

ENST00000347624 — 2 exons

Exon	Start	End
ENSE00001368094	194369661	194369743
ENSE00003690748	194355249	194361046

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 98.99.

FANTOM5 (CAGE): breadth broad, TPM avg 11.1571 / max 1010.9843, expressed in 637 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
46200	11.1571	637

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
periodontal ligament	UBERON:0008266	98.99	gold quality
tendon of biceps brachii	UBERON:0008188	96.93	gold quality
hair follicle	UBERON:0002073	95.95	gold quality
decidua	UBERON:0002450	95.48	gold quality
tibia	UBERON:0000979	93.66	gold quality
skin of hip	UBERON:0001554	93.52	gold quality
upper leg skin	UBERON:0004262	82.96	gold quality
cartilage tissue	UBERON:0002418	81.91	gold quality
upper arm skin	UBERON:0004263	79.73	gold quality
tendon	UBERON:0000043	78.34	gold quality
mucosa of paranasal sinus	UBERON:0005030	78.03	gold quality
trabecular bone tissue	UBERON:0002483	77.07	gold quality
calcaneal tendon	UBERON:0003701	74.82	gold quality
layer of synovial tissue	UBERON:0007616	74.74	gold quality
diaphragm	UBERON:0001103	71.42	gold quality
visceral pleura	UBERON:0002401	71.33	gold quality
cervix squamous epithelium	UBERON:0006922	71.16	silver quality
epithelial cell of pancreas	CL:0000083	70.68	silver quality
ileal mucosa	UBERON:0000331	68.80	gold quality
rectum	UBERON:0001052	68.43	gold quality
mammalian vulva	UBERON:0000997	68.42	gold quality
gingiva	UBERON:0001828	67.89	gold quality
pancreatic ductal cell	CL:0002079	67.77	silver quality
tibialis anterior	UBERON:0001385	67.21	silver quality
pleura	UBERON:0000977	64.97	silver quality
tongue squamous epithelium	UBERON:0006919	64.88	gold quality
zone of skin	UBERON:0000014	64.69	gold quality
gall bladder	UBERON:0002110	63.81	gold quality
skin of abdomen	UBERON:0001416	63.68	gold quality
nipple	UBERON:0002030	63.48	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

172 targeting LRRC15, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-3140-3P	99.88	68.47	2069

Literature-anchored findings (GeneRIF, showing 20)

• LRRC15 is induced by EWS-WT1(+KTS) in the tumor DSRCT and may play a role in cellular invasion. (PMID:12923058)
• Lib may contribute to regulation of cell-matrix adhesion interactions with respect to astrocyte recruitment around senile plaques in Alzheimer’s disease brain (PMID:16098915)
• Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy are presented. (PMID:18385238)
• LRRC15 expression is significantly upregulated in human masticatory mucosa during wound healing (PMID:28005267)
• LRRC15 cancer-positive models as a monotherapy. (PMID:29764866)
• Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. (PMID:32902907)
• Expression level of leucine-rich repeat containing 15 regulates characteristics of dermal papilla cells of human hair follicle. (PMID:33323297)
• Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration. (PMID:33960636)
• Transcriptomic and epigenomic analyses uncovered Lrrc15 as a contributing factor to cartilage damage in osteoarthritis. (PMID:34702854)
• Cancerassociated fibroblastderived LRRC15 promotes the migration and invasion of triplenegative breast cancer cells via Wnt/betacatenin signalling pathway regulation. (PMID:34726255)
• [Eukaryotic expression and antigen epitope prediction of the LRRC15 protein in excretory secretory antigens of Taenia solium cysticercus]. (PMID:35896492)
• LRRC15 inhibits SARS-CoV-2 cellular entry in trans. (PMID:36228039)
• Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence. (PMID:36522333)
• RUNX1 Ameliorates Rheumatoid Arthritis Progression through Epigenetic Inhibition of LRRC15. (PMID:36625319)
• The Elusive Coreceptors for the SARS-CoV-2 Spike Protein. (PMID:36680105)
• LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein. (PMID:36735681)
• Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs. (PMID:36757924)
• Leucine-Rich Repeat Containing 15-Mediated Cell Adhesion Is Essential for Integrin Signaling in TGF-beta1-Induced PDL Fibroblastic Differentiation. (PMID:38051601)
• Integrated bioinformatics analysis identified leucine rich repeat containing 15 and secreted phosphoprotein 1 as hub genes for calcific aortic valve disease and osteoarthritis. (PMID:38566328)
• Effect of LRRC15 on autophagy in A549 cells. (PMID:38763774)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lrrc15	ENSMUSG00000052316
rattus_norvegicus	Lrrc15	ENSRNOG00000068415

Paralogs (22): DCN (ENSG00000011465), RTN4R (ENSG00000040608), ASPN (ENSG00000106819), FLRT3 (ENSG00000125848), FLRT1 (ENSG00000126500), LRRC4 (ENSG00000128594), LRRC4B (ENSG00000131409), PODNL1 (ENSG00000132000), LRTM1 (ENSG00000144771), LRRC4C (ENSG00000148948), LRRTM1 (ENSG00000162951), PODN (ENSG00000174348), LRRTM4 (ENSG00000176204), BGN (ENSG00000182492), LRRC19 (ENSG00000184434), FLRT2 (ENSG00000185070), GP1BA (ENSG00000185245), RTN4RL1 (ENSG00000185924), RTN4RL2 (ENSG00000186907), NYX (ENSG00000188937), LRRC66 (ENSG00000188993), LRRTM3 (ENSG00000198739)

Protein

Protein identifiers

Leucine-rich repeat-containing protein 15 — Q8TF66 (reviewed: Q8TF66)

Alternative names: Leucine-rich repeat protein induced by beta-amyloid homolog

All UniProt accessions (1): Q8TF66

UniProt curated annotations — full annotation on UniProt →

Function. (Microbial infection) Modulates the ability of SARS-CoV-2 to infect host cells through interaction with the spike protein. Does not act as a SARS-CoV-2 entry receptor but sequesters virions and antagonizes in trans SARS-CoV-2 infection of ACE2(+) cells when expressed on nearby cells.

Subunit / interactions. (Microbial infection) Interacts with human coronavirus SARS-CoV-2 spike protein (via RBD domain); the interaction is direct and sequesters virions at the cell surface. (Microbial infection) Interacts with human coronavirus SARS-CoV-2 spike protein (via RBD domain); the interaction is direct. (Microbial infection) Interacts with human coronavirus SARS-CoV-2 spike protein (via RBD domain); the interaction is direct.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in brain and placenta. Expressed in lung fibroblasts. Expressed in chodrocytes.

Induction. In fiboblasts, expression is strongly induced by TGFB1. In chodrocytes, expression is induced by IL1B. (Microbial infection) In alveolar cells and fibroblasts, expression is induced by Sars-CoV-2 infection.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TF66-1	1	yes
Q8TF66-2	2

RefSeq proteins (2): NP_001128529, NP_570843* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR050328	Dev_Immune_Receptor	Family

Pfam: PF00560, PF13855

UniProt features (29 total): repeat 15, topological domain 2, domain 2, glycosylation site 2, sequence variant 2, signal peptide 1, chain 1, region of interest 1, compositionally biased region 1, splice variant 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TF66-F1	84.02	0.75

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 75, 369

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 147 (showing top): TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP, MCLACHLAN_DENTAL_CARIES_UP, GOBP_SYNAPSE_ASSEMBLY, NKX25_02, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GOBP_MODULATION_OF_PROCESS_OF_ANOTHER_ORGANISM, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, LHX3_01, NAGASHIMA_NRG1_SIGNALING_UP, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION, WEI_MYCN_TARGETS_WITH_E_BOX

GO Biological Process (6): positive regulation of cell migration (GO:0030335), host-mediated suppression of symbiont invasion (GO:0046597), receptor-mediated virion attachment to host cell (GO:0046813), positive regulation of synapse assembly (GO:0051965), negative regulation of protein localization to plasma membrane (GO:1903077), entry receptor-mediated virion attachment to host cell (GO:0098670)

GO Molecular Function (6): fibronectin binding (GO:0001968), collagen binding (GO:0005518), signaling receptor activity (GO:0038023), laminin binding (GO:0043236), protein sequestering activity (GO:0140311), protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), apical plasma membrane (GO:0016324), extracellular exosome (GO:0070062), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	3
cell migration	1
regulation of cell migration	1
positive regulation of cell motility	1
innate immune response	1
host-mediated perturbation of symbiont process	1
signaling receptor binding	1
virion attachment to host cell	1
synapse assembly	1
positive regulation of nervous system development	1
regulation of synapse assembly	1
positive regulation of cell junction assembly	1
protein localization to plasma membrane	1
regulation of protein localization to plasma membrane	1
negative regulation of protein localization to cell periphery	1
negative regulation of protein localization to membrane	1
receptor-mediated virion attachment to host cell	1
protein-containing complex binding	1
molecular transducer activity	1
extracellular matrix binding	1
molecular sequestering activity	1
binding	1
membrane	1
cell periphery	1
apical part of cell	1
plasma membrane region	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1370 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRRC15	VSIG8	P0DPA2	466
LRRC15	BGN	P13247	426
LRRC15	ITGB1	P05556	420
LRRC15	SMAD3	P84022	419
LRRC15	FAP	Q12884	355
LRRC15	COL11A1	P12107	353
LRRC15	BAIAP3	O94812	313
LRRC15	B4GALT4	O60513	306
LRRC15	PRR9	Q5T870	305
LRRC15	POSTN	Q15063	305
LRRC15	KRABD1	C9JBD0	305
LRRC15	PLPP4	Q5VZY2	303
LRRC15	THY1	P04216	302
LRRC15	DNAI4	Q5VTH9	301
LRRC15	THBS2	P35442	298

IntAct

128 interactions, top by confidence:

A	B	Type	Score
ATG101	ATG13	psi-mi:“MI:0914”(association)	0.950
OAZ3	AZIN1	psi-mi:“MI:0914”(association)	0.800
SMARCD1	ARID1A	psi-mi:“MI:0914”(association)	0.790
QRSL1	GATB	psi-mi:“MI:0914”(association)	0.790
USP1	PHLPP1	psi-mi:“MI:0914”(association)	0.740
PSMD7	PSMD11	psi-mi:“MI:0914”(association)	0.730
KIF3A	KIF3C	psi-mi:“MI:0914”(association)	0.730
POLR2J	POLR2D	psi-mi:“MI:0914”(association)	0.730
CTSV	CTSL	psi-mi:“MI:0914”(association)	0.720
ANXA9	PPL	psi-mi:“MI:0914”(association)	0.660
SLC27A6	TTC4	psi-mi:“MI:0914”(association)	0.640
CAPZA2	CNOT1	psi-mi:“MI:0914”(association)	0.640
LRRC15	TCAF2	psi-mi:“MI:0914”(association)	0.560
TCAF2	LRRC15	psi-mi:“MI:0915”(physical association)	0.560
GDF5	SERPINB7	psi-mi:“MI:0914”(association)	0.530
CPLX3	CIAO1	psi-mi:“MI:0914”(association)	0.530
HEATR1	DUSP14	psi-mi:“MI:0914”(association)	0.530
MRPL38	DUSP14	psi-mi:“MI:0914”(association)	0.530
OR51E2	DUSP14	psi-mi:“MI:0914”(association)	0.530
LACC1	DUSP14	psi-mi:“MI:0914”(association)	0.530
CFAP210	DUSP14	psi-mi:“MI:0914”(association)	0.530
SYT16	DUSP14	psi-mi:“MI:0914”(association)	0.530
FBXL4	DUSP14	psi-mi:“MI:0914”(association)	0.530
TFG	CRYAB	psi-mi:“MI:0914”(association)	0.530
ELMOD1	LDHC	psi-mi:“MI:0914”(association)	0.530
DFFB	UBB	psi-mi:“MI:0914”(association)	0.530
RAB40AL	VSIG8	psi-mi:“MI:0914”(association)	0.530
DOLPP1	VSIG8	psi-mi:“MI:0914”(association)	0.530
CACNB3	CACNB4	psi-mi:“MI:0914”(association)	0.530
FNTB	YKT6	psi-mi:“MI:0914”(association)	0.530

BioGRID (204): LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS)

ESM2 similar proteins: A1A4H9, A6NDA9, B1H134, B1H234, D3ZAL8, D3ZTV3, D4A6D8, E5DHB5, F1LW30, F1NUK7, O43155, P58874, P83286, Q3SXY7, Q504C1, Q5R6B1, Q5R6T0, Q5R7M3, Q5RAC4, Q6PFC5, Q6RKD8, Q70AK3, Q7TNJ4, Q80ZD7, Q80ZD8, Q80ZD9, Q810B7, Q810B8, Q810C0, Q810C1, Q86SJ2, Q86UE6, Q86VH5, Q86WK6, Q8BGT1, Q8BLU0, Q8BZ81, Q8C110, Q8IW52, Q8K1S2

Diamond homologs: A6NDA9, A8WHP9, Q80X72, Q8R5M3, Q8TF66, A3KNN3, E5DHB5, F7D3V9, Q86UN3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

132 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	121
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

373 predictions. Top by Δscore:

Variant	Effect	Δscore
3:194369655:A:AC	donor_gain	0.9900
3:194369656:C:CC	donor_gain	0.9900
3:194369657:TTA:T	donor_loss	0.9900
3:194369658:TA:T	donor_loss	0.9900
3:194369659:A:AC	donor_gain	0.9900
3:194369660:C:CC	donor_gain	0.9900
3:194369660:CCAG:C	donor_gain	0.9900
3:194367089:C:CT	donor_gain	0.9800
3:194367090:T:TT	donor_gain	0.9800
3:194369660:CCA:C	donor_gain	0.9800
3:194369659:AC:A	donor_gain	0.9700
3:194369660:CC:C	donor_gain	0.9700
3:194361046:CCTG:C	acceptor_gain	0.9600
3:194369651:G:A	donor_gain	0.9600
3:194369659:ACCAG:A	donor_gain	0.9600
3:194369660:CCAGC:C	donor_gain	0.9600
3:194361043:TAGC:T	acceptor_gain	0.9100
3:194361044:AGCC:A	acceptor_loss	0.9000
3:194361045:GCC:G	acceptor_loss	0.9000
3:194361047:C:CG	acceptor_loss	0.9000
3:194361048:T:A	acceptor_loss	0.9000
3:194369656:CTTA:C	donor_gain	0.9000
3:194368673:TGGC:T	donor_gain	0.8900
3:194361047:C:CC	acceptor_gain	0.8700
3:194367088:A:C	donor_gain	0.8600
3:194361049:G:C	acceptor_gain	0.8300
3:194361045:GC:G	acceptor_gain	0.8200
3:194359307:A:AC	donor_gain	0.8100
3:194361015:A:T	acceptor_gain	0.8100
3:194369658:T:TG	donor_gain	0.8100

AlphaMissense

3814 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:194360583:A:G	L154P	1.000
3:194359769:C:A	W425C	0.999
3:194359769:C:G	W425C	0.999
3:194359771:A:G	W425R	0.999
3:194359771:A:T	W425R	0.999
3:194359857:A:G	L396P	0.999
3:194359929:A:G	L372P	0.999
3:194360001:A:G	L348P	0.999
3:194360079:A:G	L322P	0.999
3:194360151:A:G	L298P	0.999
3:194360217:A:G	L276P	0.999
3:194360279:G:C	N255K	0.999
3:194360279:G:T	N255K	0.999
3:194360289:A:G	L252P	0.999
3:194360295:A:G	L250P	0.999
3:194360361:A:G	L228P	0.999
3:194360367:A:G	L226P	0.999
3:194360439:A:G	L202P	0.999
3:194360439:A:T	L202H	0.999
3:194360511:A:G	L178P	0.999
3:194360511:A:T	L178H	0.999
3:194360567:G:C	N159K	0.999
3:194360567:G:T	N159K	0.999
3:194360639:G:C	N135K	0.999
3:194360639:G:T	N135K	0.999
3:194360655:A:G	L130P	0.999
3:194360711:G:C	N111K	0.999
3:194360711:G:T	N111K	0.999
3:194360713:T:A	N111Y	0.999
3:194360721:A:G	L108P	0.999

dbSNP variants (sampled 300 via entrez): RS1000376702 (3:194369105 A>T), RS1001136357 (3:194356564 T>C), RS1001198789 (3:194357888 A>G), RS1001201698 (3:194366839 G>A,T), RS1001209736 (3:194361942 T>C), RS1001289273 (3:194371021 C>T), RS1001406640 (3:194362202 A>G,T), RS1001437232 (3:194357552 T>A,C), RS1001484489 (3:194356283 T>G), RS1001863177 (3:194358960 G>A), RS1002185286 (3:194367366 G>A), RS1002344674 (3:194371321 G>T), RS1002389318 (3:194371215 G>A,C), RS1002408175 (3:194371719 C>T), RS1002929479 (3:194368305 C>G,T)

Disease associations

OMIM: gene MIM:619327 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295907 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

3 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs11313667	Efficacy	3	atenolol	Hypertension
rs11313667	Efficacy	3	metoprolol	Hypertension
rs11313667	Efficacy	3	hydrochlorothiazide	Hypertension

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs11313667	LRRC15	3	0.00	3	hydrochlorothiazide;metoprolol;atenolol

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
sodium arsenite	increases expression	2
aristolochic acid I	decreases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
trimellitic anhydride	decreases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
didecyldimethylammonium	decreases expression	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
CGP 52608	affects binding, increases reaction	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
abrine	increases expression	1
licochalcone B	increases expression	1
Capecitabine	decreases expression	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Bleomycin	increases expression	1
Cadmium	decreases reaction, increases abundance, increases palmitoylation	1
Calcitriol	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Lipopolysaccharides	increases expression, decreases reaction	1
Tetrachlorodibenzodioxin	increases expression	1
Thiram	increases expression	1
Urethane	increases expression	1
Vanadates	increases expression	1
Cadmium Chloride	decreases reaction, increases abundance, increases palmitoylation	1
Okadaic Acid	increases expression	1
Genistein	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118670	Binding	Binding affinity to LRRC15 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.